<DOC>
	<DOCNO>NCT00645749</DOCNO>
	<brief_summary>The hypothesis study helminth-induced immunomodulation therapy ( HINT ) safe effective administer orally patient relapsing-remitting multiple sclerosis ( RRMS ) .</brief_summary>
	<brief_title>Helminth-induced Immunomodulation Therapy ( HINT ) Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description>Phase 1 HINT trial complete enrollment 5 subject . HINT Phase 2 close enrollment 15 subject . Recruitment sit UW-Madison Marshfield Clinic .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>McDonald Committee ( 2010 ) criterion RRMS ( MS ) . ambulatory patient disability score EDSS 0.5.0 male female subject ; age 1850 diagnosis within three year study entry , base either ) two clinical attack three year prior entry b ) one attack within three year entry , couple MRI evidence dissemination space time strict application McDonald Committee MRI criterion active MRI entry , evidence least one gd+ enhance lesion screen explicit refusal treat conventional diseasemodifying medication ( DMT ) RRMS , full discussion potential benefit risk agent review National Multiple Sclerosis Advisory Statement DMT . ability provide write informed consent patient unwilling unable give write informed consent follow protocol successfully allergy Trichuris specie treatment metronidazole ( Flagyl ) medication antihelminth effect ( IB 5.7 ) previous anticipate treatment FDAapproved experimental medication RRMS previous treatment immunosuppressive therapy , cytotoxic chemotherapy , lymphoid irradiation reason insulin dependent diabetes mellitus history HIV1 , HTLV1 , viral hepatitis , Lyme disease . requirement chronic , sustain aspirin nonsteroidal antiinflammatory medication ( e.g. , use 56 day per month transient symptom ) significant physical mental disease would preclude successful compliance participation study , opinion principal investigator , constitute hazard , enrollment study would patient 's best interest . presence history cancer type ( except successfully treat basal cell squamous cell carcinoma skin ) history alcohol drug abuse last 12 month ; chronic liver biliary disease ; AST ALT determination great two time upper limit normal follow laboratory abnormality : serum creatinine &gt; 1.7 mg/DL , white blood count &lt; 3,500/mm3 , lymphocyte count &lt; 800/mm3 special subject minor child , mentally disabled person , prisoner contraindication MRI scanning , include significant claustrophobia sensitivity gadolinium contrast agent pregnancy lactation ; woman childbearing potential must document negative serum beta HCG pregnancy test entry study must willing practice adequate birth control duration study MS attack treatment corticosteroid medication within 30 day study entry ( corticosteroid may use study MS relapse per judgment treat physician , IB 5.7 , IB 6.1.3 ) immediate household family contact immunodeficient immunosuppressed history parasitism positive determination ovum parasite stool screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>